

Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy

Sinead E. Morris¹, Renate Strehlau², Stephanie Shiao³, Elaine J. Abrams^{4,5,6},
Caroline T. Tiemessen⁷, Louise Kuhn^{4,8}, Andrew J. Yates¹,
on behalf of the EPIICAL Consortium and the LEOPARD study team

¹Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA

²Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

³Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, 08854, USA

⁴Department of Epidemiology, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA

⁵ICAP at Columbia University, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA

⁶Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University Medical Center, New York, NY, USA

⁷Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services, and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

⁸Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA

Abstract

1 In 2019 there were 490,000 children under five living with HIV. Understanding the dynamics of HIV suppression
2 and rebound in this age group is crucial to optimizing treatment strategies and increasing the likelihood of infants
3 achieving and sustaining viral suppression. Here we studied data from a cohort of 122 perinatally-infected
4 infants who initiated antiretroviral treatment (ART) early after birth and were followed for up to four years. These
5 data included longitudinal measurements of viral load (VL) and CD4 T cell numbers, together with information
6 regarding treatment adherence. We previously showed that the dynamics of HIV decline in 53 of these infants
7 who suppressed VL within one year were similar to those in adults. However, in extending our analysis to all 122
8 infants, we find that a deterministic model of HIV infection in adults cannot explain the full diversity in infant
9 trajectories. We therefore adapt this model to include imperfect ART adherence and natural CD4 T cell decline
10 and reconstitution processes in infants. We find that individual variation in both processes must be included
11 to obtain the best fits. We also find that, perhaps paradoxically, infants with faster rates of CD4 reconstitution
12 on ART were more likely to experience resurgences in VL. Overall, our findings highlight the importance of
13 combining mathematical modeling with clinical data to disentangle the role of natural immune processes and
14 viral dynamics during HIV infection.

15 **Keywords:** HIV, infants, ART, mathematical model, viral dynamics, rebound, latent reservoir

16 Author Summary

17 For infants infected with HIV at or near birth, early and continued treatment with antiretroviral therapy (ART)
18 can lead to sustained suppression of virus and a healthy immune system. However many treated infants expe-
19 rience viral rebound and associated depletion of CD4 T cells. Mathematical models can successfully capture
20 the dynamics of HIV infection in treated adults, but many of the assumptions encoded in these models do not
21 apply early in life. Here we study data from a cohort of HIV-positive infants exhibiting diverse trajectories in
22 response to ART. We show that wide-ranging outcomes can be explained by a modified, but still remarkably
23 simple, model that includes both the natural dynamics of their developing immune systems and variation in
24 treatment adherence. Strikingly, we show that infants with strong rates of recovery of CD4 T cells while on ART
25 may be most at risk of virus resurgence.

26 Introduction

27 In 2019 there were 490,000 children under five living with HIV, and 150,000 newly diagnosed cases [1]. Al-
28 though infants receiving antiretroviral treatment (ART) can suppress viral load (VL), eventually the cessation
29 of treatment leads to HIV rebound, due to reactivation of latently-infected cells. Nevertheless, early initiation of
30 ART can lead to extended periods of suppression in the absence of treatment – for example, over 22 months in
31 the case of the ‘Mississippi Child’ and 8.75 years in a South African participant of the Children with HIV Early
32 antiRetroviral therapy (CHER) trial [2, 3]. Therefore, understanding the dynamics of HIV suppression and re-
33 bound following ART initiation in young infants is crucial for optimizing treatment strategies and increasing
34 the likelihood of achieving and sustaining viral suppression.

35 We previously showed that a simple biphasic model of VL decay captures the early dynamics of HIV decline in
36 perinatally-infected infants on ART and that these dynamics are similar to those in adults [4]. However, mod-
37 els applied to dynamics of infection in adults over longer timescales typically encode assumptions that do not
38 extend to infants [5–12]. First, CD4 T cell dynamics in adults are typically described as a balance between a
39 constant total rate of influx and a constant *per capita* rate of loss, leading to steady trajectories in the absence of
40 infection. In contrast, HIV-uninfected infants experience a natural, exponential decline in CD4 T cell numbers
41 per unit volume of blood as the immune system matures [13]. Second, perinatally-infected infants undergo a
42 transient period of CD4 T cell reconstitution upon ART initiation, during which numbers quickly recover to
43 those of HIV-uninfected infants [14]. This short-lived process cannot be captured by the constant CD4 recruit-
44 ment term exploited in many models of adult infection. Third, the standard assumption that ART is completely
45 effective in blocking new infection of cells may not hold true for young infants, due to challenges in treatment
46 adherence. Thus, canonical models of HIV suppression and rebound in adults must be modified for infants to
47 include potential reductions in ART efficacy, and more complex dynamics of CD4 T cell numbers.

48 Here we model the dynamics of HIV infection in a cohort of perinatally-infected infants from Johannesburg,
49 South Africa who initiated ART early in life. We extend a simple deterministic model of HIV suppression and
50 rebound in adults to incorporate incomplete treatment adherence and dynamics of natural CD4 T cell decline
51 and reconstitution. By fitting this model to longitudinal viral RNA and CD4 T cell data, we estimate rates of
52 reactivation and reconstitution. We also show that individual variation in CD4 reconstitution rates are an im-

53 portant factor driving variation in HIV suppression and resurgence characteristics across infants, in addition to
54 ART adherence. Overall, our results demonstrate the complex interplay between natural immune processes and
55 HIV dynamics, and highlight the importance of mathematical modeling in disentangling these factors.

56 **Methods**

57 **Data**

58 The LEOPARD study has been described previously [4, 15]. Briefly, 122 perinatally-infected infants were en-
59 rolled at the Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa, between 2014 and 2017.
60 The majority began ART within two weeks of birth (median age: 2.5 days; interquartile range (IQR): 1–8), and
61 were followed for up to four years. VL (HIV RNA copies ml⁻¹) and CD4 T cell concentrations (cells μl⁻¹) in
62 the blood were sampled over time, and various clinical covariates were also recorded, including the infant's
63 pre-treatment CD4 percentage, the mother's VL and CD4 count after delivery, and the mother's prenatal ART
64 history (full list in Table S1).

65 With these data, we previously identified a subset of 53 infants who successfully suppressed VL within one
66 year [4, 16], with suppression defined as having at least one VL measurement below the 20 copies ml⁻¹ detection
67 threshold of the RNA assay. Here, we are interested in the interplay between natural CD4 T cell dynamics and
68 infection processes, and whether and how this interplay determines whether an infant achieves suppression
69 and/or experiences VL rebound. We have therefore broadened our analysis to all 122 infants.

70 In addition to the data described previously, we include information relating to ART adherence that was obtained
71 at each study visit (details in SI). For each drug in each infant's ART regimen – with the recommended, and most
72 common, being zidovudine (AZT), lamivudine (3TC), and (i) nevirapine (NVP) in the first four weeks of treat-
73 ment, then (ii) ritonavir-boosted lopinavir (LPV/r) after four weeks – we estimated a percentage adherence by
74 comparing the weight of medicine returned to the expected amount returned assuming perfect adherence. Less
75 than 100% adherence can result from missed doses or 'under-dosing' (giving too little medicine at each dose),
76 whereas greater than 100% adherence can occur through over-dosing or problems with drug tolerance (infants
77 may spit up bad-tasting medicine, therefore requiring repeat dosing). For many visits, adherence could not be
78 calculated because leftover medicine was not returned. The adherence estimates are therefore influenced by
79 many unobserved factors and, given uncertainty in how the quantitative estimates map to actual adherence, we
80 instead defined a categorical variable that labeled adherence estimates greater than 90% as 'good', and estimates
81 less than 90% as 'poor'. Using 85% and 95% as alternative thresholds for good adherence did not alter our find-
82 ings. With this course-grained approach, some missing values could be manually labelled based on physician
83 commentary from accompanying questionnaires (for example, if substantial gaps in dosing were noted, adher-
84 ence was labeled as poor). We then summarized the average adherence of each infant as the most frequently
85 reported category (good or poor) across their time series.

86 **Ethics statement**

87 All protocols for the LEOPARD study were approved by the Institutional Review Boards of the University of the
88 Witwatersrand and Columbia University. Written informed consent was obtained from mothers for their own

89 and their infants' participation.

90 Model

91 We describe HIV dynamics in an infant on ART using a deterministic ordinary differential equation (ODE)
92 model (Fig 1A) [7, 12]. We assume that CD4 target cells, $T(t)$ (measured as the concentration of cells per μ l
93 of blood, but from here on referred to as 'cells' or 'counts' for brevity), undergo background growth and loss
94 according to a function $\theta(t, T)$, and are infected by free virus, $V(t)$, at *per capita* transmission rate β (Table 1).
95 During ART this transmission is blocked with efficacy ϵ_1 , where $\epsilon_1 < 1$ reflects incomplete adherence of reverse
96 transcriptase inhibitor drugs that block infection of new cells (for example, NVP and AZT). A proportion $(1 - \rho)$
97 of the newly infected target cells seed the latent reservoir; the remaining fraction, ρ , either become productively
98 infected or die through abortive infection [17]. Cells from this heterogeneous infected population, $I(t)$, are lost
99 at an average rate d , and produce virus at an average rate $(1 - \epsilon_2)p$, where p subsumes the fraction of cells that
100 are productively infected and $\epsilon_2 < 1$ reflects any failure of protease inhibitors (for example, LPV/r) to block the
101 production of infectious virus. The infected cell population is also boosted by reactivation of the latent reservoir,
102 at rate a . We do not explicitly model the number of latently infected cells due to uncertainties in the rates of
103 proliferation and loss in this population, and a lack of available data to estimate these parameters. Finally, free
104 virus is lost at rate c . This system can be represented by the following equations

$$\begin{aligned}\frac{dT}{dt} &= \theta(t, T) - (1 - \epsilon_1)\beta VT \\ \frac{dI}{dt} &= \rho(1 - \epsilon_1)\beta VT - dI + a \\ \frac{dV}{dt} &= (1 - \epsilon_2)pI - cV.\end{aligned}$$

105 The reproduction number for this model at ART initiation is

$$R_0 = \frac{\rho(1 - \epsilon_1)(1 - \epsilon_2)\beta p T_0}{cd},$$

106 where T_0 is the initial CD4 count (assuming contribution from the latent reservoir is negligible at this time).

107 In the simplest case we assume all rate parameters are constant over time. However, we also investigate an
108 extension of this model that incorporates a delay in reactivation of the latent reservoir,

$$a = \begin{cases} 0 & \text{if } t \leq T_A \\ \bar{a} & \text{if } t > T_A, \end{cases}$$

109 where T_A is the time to reactivation in days. Assuming the rate of virus turnover is faster than that of CD4 T
110 cells [18], we reduce the model to the following system




Figure 1: **Model framework and analysis schematic.** (A) Framework for the infection model with rate constants. CD4 target cells (T) are infected by free virus (V) and either become productively infected cells (I) or latently infected cells. Productively infected cells produce free virus whereas latently infected cells do not; but latently infected cells can become reactivated at a later point to join the productively infected cell population. CD4 target cells also undergo reconstitution and natural decline processes according to $\theta(t, T)$. Further details are given in the text. (B) Schematic illustrating the definition of viral resurgence (top) compared to no resurgence (bottom). The timing of resurgence is defined as the time at which VL first starts increasing (vertical red line), and the size of resurgence is the total integrated VL during the upslope period (blue shaded region). The dashed horizontal line represents the assay detection threshold.

$$\begin{aligned}\frac{dT}{dt} &= \theta(t, T) - \beta_0 VT \\ \frac{dV}{dt} &= \rho\bar{c}\beta_0 VT - dV + a\bar{c},\end{aligned}$$

111 where $\beta_0 = (1 - \epsilon_1)\beta$ and $\bar{c} = (1 - \epsilon_2)p/c$ (derivation in the SI). The compound parameter \bar{c} represents the
 112 contribution of each infected cell to the total viral load, through its rate of production of virions and the average
 113 time they persist in circulation. Both β_0 and \bar{c} incorporate ART efficacy (through ϵ_1 and ϵ_2), and thus infant
 114 ART adherence.

115 Finally, we extend the model for young infants through the term governing background CD4 T cell growth and
 116 loss, $\theta(t, T)$. In models of infection dynamics in adults, $\theta(t, T)$ typically takes the form $\lambda - d_T T$, where λ and d_T
 117 are constant rates representing cell influx and natural decay processes, respectively. These forms lead to steady
 118 trajectories in the absence of infection. For infants, we propose an alternative $\theta(t, T)$ that instead accounts for
 119 (i) the exponentially declining concentration of CD4 T cells that is observed as HIV-uninfected infants age [13],
 120 and (ii) the transient recovery in CD4 counts experienced by HIV-infected infants during the early stages of
 121 ART [14]. First, the natural decline in CD4 T cells can be captured by an exponential decay function

$$T = c_0 + b_0(1 - e^{b_1 t}),$$

122 where c_0 , b_0 and b_1 are constant parameters that have been independently estimated in a cohort of 80 uninfected
123 children in Germany, including 39 aged between 2 months and 4 years [13]. This function also captured CD4
124 T cell dynamics in 381 South African children, of whom 300 were aged between 2 weeks and 5 years [19].
125 Second, the additional reconstitution of the CD4 T cell pool in HIV-infected infants can be modeled as a transient
126 increase in cell counts during the early stages of ART, i.e.

$$\frac{dT}{dt} = \begin{cases} r & \text{if } t \leq T_R \\ 0 & \text{if } t > T_R, \end{cases}$$

127 where r is the constant rate of reconstitution and T_R is the time to reach healthy levels [14]. Combining these
128 processes of reconstitution and the natural decline of CD4 T cell counts in infants gives $\theta(t, T) = -b_1 b_0 e^{b_1 t} + \bar{r}$,
129 and

$$\frac{dT}{dt} = -b_1 b_0 e^{b_1 t} + \bar{r} - \beta_0 VT \quad (1)$$

$$\frac{dV}{dt} = \rho \bar{c} \beta_0 VT - dV + a \bar{c}, \quad (2)$$

130 where

$$\bar{r} = \begin{cases} r & \text{if } t \leq T_R \\ 0 & \text{if } t > T_R. \end{cases}$$

131 Model fitting and comparisons

132 We fit equations 1 and 2 to the VL and CD4 T cell data from all 122 infants using a nonlinear mixed effects
133 approach. All VL observations below the detection threshold were treated as censored values, and we assumed
134 both $V(t)$ and $T(t)$ were lognormally distributed [20, 21]. Given the relative infrequency of CD4 T cell mea-
135 surements, we fixed four parameters across all individuals (Table 1): three that governed the reconstitution and
136 natural dynamics of target cells (T_R , b_0 and b_1), and the proportion of newly infected cells that become pro-
137 ductively infected (ρ). All other parameters were estimated and allowed to have both fixed and random effects.
138 In subsequent analyses we estimated fixed and random effects for T_R . We also examined the importance of
139 individual variation in adherence and CD4 T cell recovery by comparing the best fit model to three alternative
140 models in which β_0 , \bar{c} or r were fixed across all infants.

141 Following exploratory fits, each estimated parameter was assumed to follow a lognormal distribution, with the
 142 exception of a which followed a logit-normal distribution with pre-specified upper bound, and r and T_R which
 143 followed normal distributions. We verified that the random effects for all estimated parameters were normally
 144 distributed, using the Shapiro-Wilk test. Guided by the exploratory fits, we allowed β_0 and d to be correlated,
 145 and assumed all other parameters were independent. We confirmed the identifiability of all parameters [22], and
 146 conducted additional sensitivity analyses by varying each chosen parameter in turn and re-simulating the model,
 147 while keeping all other parameters fixed. We used these simulations to assess the sensitivity of model predic-
 148 tions to our choice of fixed parameters. Model fitting and parameter estimation were implemented in Monolix
 149 2020R1 [21]. Downstream analyses and plotting were conducted in R version 4.03 [23], with the `deSolve`,
 150 `cowplot`, `patchwork` and `tidyverse` packages [24–27]. All details needed to reproduce our analyses are
 151 given in the SI.

Table 1: Model parameters and population-level estimates.

Parameter	Description	Units	Value, if fixed	Mean (SE), if estimated*
$\beta_0 = (1 - \epsilon_1)\beta$	Per-cell effective transmission rate	(copies ml ⁻¹) ⁻¹ day ⁻¹		5 (1) × 10 ⁻⁸
ρ	Proportion of cell infections that are productive	–	0.9999 [5, 28]	
$\bar{c} = (1 - \epsilon_2)p/c$	Ratio of viral production to loss	copies ml ⁻¹ cell ⁻¹		220 (76)
d	Rate of infected cell loss	day ⁻¹		0.05 (0.006)
a	Total rate of latent reservoir reactivation	cells day ⁻¹		0.001 (0.001)
b_0	Extent of natural CD4 T cell decline	cells	-2354 [13]	
$-1/b_1$	Timescale of natural CD4 T cell decline	days	1003 [13]	
r	Rate of CD4 T cell reconstitution	cells day ⁻¹		8.0 (0.4)
T_R	Age at reconstitution plateau	days	170–300 [†] [14]	
T_0	Initial number of CD4 T cells	cells		1612 (80)
V_0	Initial viral load	copies ml ⁻¹		5077 (1259)

*Estimates taken from the model with lowest AIC.

[†]A range of values were explored around previous estimates [14].

SE = standard error (random effect) around the population mean (fixed effect); cells = cells μl^{-1} .

152 We compared the statistical support for different models using the Akaike Information Criterion (AIC). For
 153 model i , $\text{AIC}_i = 2k - 2 \ln L$, where k is the number of estimated parameters, $\ln L$ is the maximum log-
 154 likelihood, and lower AIC values indicate stronger statistical support. We assessed the relative support for model
 155 i using $\Delta\text{AIC}_i = \text{AIC}_i - \text{AIC}_{\min}$, where AIC_{\min} is the minimum AIC value across all models. Differences greater
 156 than five indicate substantially greater support for the model with $\text{AIC}_i = \text{AIC}_{\min}$. For the favored model, we
 157 used the individual-specific parameter estimates to predict VL and CD4 T cell trajectories for each child. These
 158 trajectories extended either to the end of our study period or two years after their last observation, whichever
 159 was earlier. We then compared how viral infection and the natural decline in CD4 T cells mediated the overall
 160 VL and CD4 T cell dynamics. We calculated the relative contributions of new viral infection and natural decline
 161 to decreases in CD4 T cell numbers as

$$\frac{\beta_0 TV}{\beta_0 TV + b_1 b_0 e^{b_1 t}} \quad \text{and} \quad \frac{b_1 b_0 e^{b_1 t}}{\beta_0 TV + b_1 b_0 e^{b_1 t}}, \quad (3)$$

162 respectively. Similarly, the relative contributions of new viral infection and latent reservoir reactivation to in-

163 creases in the number of productively infected cells were

$$\frac{\rho\beta_0TV}{\rho\beta_0TV + a} \quad \text{and} \quad \frac{a}{\rho\beta_0TV + a}, \quad (4)$$

164 respectively.

165 **Statistical analyses**

166 We tested for statistical associations between model parameters, clinical covariates (Table S1), and the risk of
167 VL resurgence – defined as any predicted increase in VL following initiation of ART (Fig 1B). We chose VL
168 resurgence as our indicator of imperfect viral control rather than VL rebound (any predicted increase in VL
169 following initial suppression of HIV) due to the small number of infants experiencing the latter (5/122 infants
170 experienced rebound compared to 52/122 experiencing resurgence). We defined the timing of VL resurgence as
171 the first point at which the model predicted an increase in VL, and the size of resurgence as the total integrated VL
172 during the upslope period (Fig 1B). We then tested for associations using Spearman correlations between pairs of
173 quantitative variables, the Kruskal Wallis test between quantitative and categorical variables, and Chi-squared
174 tests between pairs of categorical variables. We adjusted for multiple testing using the Benjamini-Hochberg
175 correction.

Results

176

177 The model for adult infection, with $\theta(t, T) = \lambda - d_T T$, was a poor fit to the infant data, particularly the
178 CD4 T cell counts (Fig S1, Table 2). We therefore used the model adapted for infant infection, with $\theta(t, T) =$
179 $-b_1 b_0 e^{b_1 t} + \bar{r}$, in all further analyses. First, we verified that the infant model with fixed time to reconstitution
180 plateau, T_R , and constant rate of latent reactivation, a , was structurally identifiable (see Table 1 and SI) [22]. We
181 initially fixed $T_R = 225$ days across all infants, following previous modeling of CD4 reconstitution in another
182 cohort of HIV-infected infants who initiated ART 82 days after birth, on average [14]. We refitted the model with
183 different fixed values and verified that the best fits were obtained when $T_R = 225$ days ($\Delta\text{AIC}_i = 8.3$ relative
184 to the next best model with $T_R = 223$ days; Table S2). Including random effects for T_R improved model fits,
185 although also estimating the fixed effect (i.e. estimating the population average of T_R) did not (Table 2). This is
186 likely due to the increased complexity introduced by estimating an additional parameter. Similarly, including a
187 delay in reactivation of the latent reservoir did not improve model fits. We therefore focus on the model with a
188 constant rate of reactivation from the latent reservoir and random effects for T_R around a predefined population
189 mean of 225 days. With this model, VL predictions were marginally sensitive to all fixed parameters (T_R , b_0 ,
190 b_1 and ρ ; Fig S2), whereas CD4 T cell dynamics were sensitive to those governing healthy T cell reconstitution
191 and decline (T_R , b_0 and b_1) but robust to changes in the proportion of new infections that become productively
192 infected cells (ρ ; Fig S3).

193 Strikingly, our relatively simple deterministic model captured the wide variation in infant VL trajectories, in-
194 cluding monotonic decreases to suppression, eventual suppression following transient increases in VL, and brief
195 periods of suppression with a subsequent rebound in VL (Fig 2). Later, or multiple, rebound occurrences were
196 generally not so well captured. These behaviors may be due to repeated fluctuations in treatment adherence
197 or stochastic processes driving delayed reactivation of the latent reservoir, neither of which are included in the
198 model. Initially, new infections were the major contributor to growth of the productively infected cell pop-
199 ulation (Eqn 4; Fig S4). However, in almost all infants the importance of new infection events was eventually
200 superseded by reactivation from the latent reservoir, although this displacement was delayed by viral resurgence
201 events and prolonged CD4 T cell recovery (Fig S5).

Table 2: **Model comparisons.** AIC values (ΔAIC) are quoted relative to the minimum AIC value across all models. The model with $\Delta\text{AIC} = 0$ is the model with lowest AIC and thus has most statistical support. See Table 1 for parameter definitions.

Model*	ΔAIC
Constant a ; fixed $T_R = 225$ days with random effect	0.0
Constant a ; fixed $T_R = 225$ days without random effect	7.1
Constant a ; estimated T_R	27.1
Time-varying a , fixed $T_R = 225$ days without random effect	31.5
$\theta(t, T) = \lambda - d_T T$	365.4

*Unless stated otherwise, $\theta(t, T) = -b_1 b_0 e^{b_1 t} + \bar{r}$.

202 The majority of infants experienced a transient increase in CD4 T cell counts followed by a steady decline; these
203 patterns were well captured by the model (Fig 3). The decline in CD4 T cells was almost always driven by




Figure 2: Model fits for RNA observations Each panel represents a different infant; points represent the data; and solid lines are the model fits. The dashed horizontal line is the detection threshold of the RNA assay, and red crosses are censored observations below this threshold. Panels shaded in red are infants who experienced viral resurgence (i.e. at least one period of increasing VL).

204 natural processes, although the contribution of new infections increased during periods of VL resurgence (Eqn 3;
205 Fig S6).

206 The fixed effects for all estimated parameters, and the standard error of the associated random effects, are given in
207 Table 1. The population-level average lifespan of productively infected cells ($1/d$) was 19 days (95% percentile
208 across all infants = 5–52 days), and R_0 at ART initiation was 0.35 (0.18–1.25), reflecting an initial decrease
209 in VL across most infants. The rate of CD4 T cell reconstitution, r , was positively correlated with the initial
210 number of CD4 T cells, T_0 , and the duration of reconstitution, T_R (Fig S7). These associations are unlikely to be
211 driven by poor parameter identifiability, which would instead cause negative correlations through compensatory
212 mechanisms. Notably, we found that infants with higher reconstitution rates, r , and VL production to decay
213 ratios, \bar{c} , were more likely to experience increases in VL after ART initiation ($p < 1 \times 10^{-4}$; Fig 4A–B), although
214 the effect was small in the former case (difference in means = 1.2% of the population average). For those infants
215 who did experience increases in VL, larger and earlier increases were associated with higher VL production to
216 decay ratios ($p < 1 \times 10^{-4}$; Fig 4C–D), but not reconstitution rates ($p > 0.5$). Overall, these results suggest that
217 VL production to decay ratios and CD4 reconstitution rates are the most important parameters determining an
218 infant's resurgence characteristics.

219 In addition to the deterministic model parameters, we found a longer duration of maternal prenatal ART was
220 associated with risk of VL resurgence ($p < 0.01$; Fig 4E). However, this covariate was also associated with higher
221 VL production to decay ratios ($p < 0.01$; Fig S9), suggesting potential colinearity. All other associations between
222 VL resurgence characteristics and clinical covariates, including pre-treatment CD4 percentage and age at ART
223 initiation (Table S1), were not significant at the $p = 0.05$ level. Taken together, these findings suggest maternal
224 prenatal ART history may mediate the risk of VL resurgence, through, or in addition to, the deterministic model
225 parameters discussed above.

226 **Variation in both adherence and the natural dynamics of CD4 T cells dictate infant trajec-** 227 **tories**

228 The most obvious explanation for the wide variety of VL suppression and resurgence trajectories we have iden-
229 tified here is variation in ART adherence, which may be more pronounced in infants than adults. In our models,
230 we assume variation in ART adherence is reflected entirely in the parameters ϵ_1 and/or ϵ_2 , which dictate the
231 efficiency of treatment at blocking new infection and virus production by infected cells, respectively. These pa-
232 rameters are not individually identifiable with these data, but instead are subsumed in the compound parameter
233 $\bar{c} = (1 - \epsilon_2)p/c$ and $\beta_0 = (1 - \epsilon_1)\beta$. (In support of this, we found that \bar{c} was associated with our measures of
234 LPV/r, NVP and AZT adherence from the study questionnaires ($p < 0.05$, Fig 4F), although β_0 was not.) Thus,
235 if adherence is the main driver of variation in VL trajectories, then individual variation in \bar{c} and β_0 should be
236 the most crucial components of our model. However, the association we detected between CD4 reconstitution
237 rates and the probability of resurgence suggest variation in CD4 T cell dynamics may also be important. To
238 explore this issue, we refit the model while removing the random effects for β_0 , \bar{c} and r in turn. We found that
239 fixing any of these parameters resulted in poorer fits, although the model with fixed r performed worst overall
240 (Table 3). This suggests that CD4 T cell dynamics are an important factor driving variation in HIV suppression
241 and resurgence characteristics across infants, in addition to ART adherence.




Figure 3: Model fits for CD4 T cell observations Each panel represents a different infant, ordered as in Fig 2; points represent the data; and solid lines are the model fits.




Figure 4: VL resurgence is associated with CD4 reconstitution, VL production and decay, and ART history of infant and mother. (A–B) Relationship between the occurrence of VL resurgence (defined as any increase in VL following initiation of ART) and the CD4 reconstitution rate, r , in cells $\mu\text{l}^{-1} \text{day}^{-1}$ (A) and ratio of VL production to decay, $\bar{c} = (1 - \epsilon_2)p/c$, in copies $\text{ml}^{-1} \text{cell}^{-1}$ (B). Each point represents a different infant and $p < 0.0001$ (****) in both cases. Five infants whose resurgence was a viral rebound event are highlighted in orange. (C–D) Relationship between \bar{c} and the size of VL resurgence in RNA copies ml^{-1} (C) and timing of VL resurgence in days (D). Each point represents an infant who experienced resurgence. Correlations are 0.61 and -0.58, respectively, and $p < 1 \times 10^{-4}$ in both cases. (E) Relationship between the occurrence of VL resurgence and the timing of maternal prenatal ART initiation ($p < 0.01$). The size of each box reflects the proportion of infants in the corresponding category and the numbers show the corresponding sample size. (F) Relationship between infant ART adherence is associated and VL production to decay ratios. Adherence was classified as ‘good’ if the majority of adherence estimates were 90% or more, and ‘poor’ otherwise. The VL production to decay ratio is given by $\bar{c} = (1 - \epsilon_2)p/c$, in copies $\text{ml}^{-1} \text{cell}^{-1}$. Each panel represents a different drug and each point represents a different infant. Significance levels are $p < 0.05$ (*); $p < 0.01$ (**).

Table 3: Model comparisons of adherence and CD4 recovery parameters. AIC values (ΔAIC) are quoted relative to the minimum AIC value across all models. The model with $\Delta\text{AIC} = 0$ is the model with lowest AIC and thus has most statistical support. See Table 1 for parameter definitions.

Model	ΔAIC
Fixed and random effects for β_0 , \bar{c} and r^*	0.0
Fixed and random effects for \bar{c} and r ; only fixed effects for β_0	30.0
Fixed and random effects for β_0 and r ; only fixed effects for \bar{c}	31.9
Fixed and random effects for β_0 and \bar{c} ; only fixed effects for r	79.6

*Corresponds to the best-fit model in Table 2.

242 Discussion

243 In this study we modeled the dynamics of HIV suppression and rebound in perinatally-infected infants receiving
244 ART. Our framework extends previous models of rebound in adults [7, 12] by incorporating mechanisms of the
245 natural decline and infection-induced reconstitution of CD4 T cells in young infants [14]. We found that new
246 infection events were initially the major contributor to growth of the productively infected cell population, but
247 that reactivation of the latent reservoir became more important once VL levels were low (Fig S4). We also
248 identified natural processes as the longterm driver of CD4 T cell declines in blood.

249 Although our estimates of the average CD4 T cell reconstitution rate ($r = 8 \text{ cells } \mu\text{l}^{-1} \text{ day}^{-1}$) is greater than
250 those from another cohort of HIV-infected infants ($r = 3.8 \text{ cells } \mu\text{l}^{-1} \text{ day}^{-1}$), it is within the interquartile ranges.
251 Notably, infants from this other cohort initiated ART later, on average, than the infants in our cohort (median
252 = 82 days, IQR = 34–121), and all eventually achieved viral suppression [14]. We also found that higher rates
253 of reconstitution were associated with a greater probability of experiencing a resurgence in VL. This relation-
254 ship was not confounded by the immunological status of infants at the beginning of the study as we found no
255 association between the reconstitution rate and pre-treatment CD4 percentage or counts, or between the risk
256 of VL resurgence and pre-treatment CD4 percentage or counts. Our finding raises the possibility that rapid re-
257 covery of CD4 T cells, despite suggesting an improved clinical state, can also increase the risk of VL resurgence
258 in some individuals by repopulating the target cell pool. Although it could also be that VL resurgence triggers
259 more rapid CD4 reconstitution through increased anti-viral immune activity or density-dependent responses to
260 CD4 depletion [14], the latter seems unlikely in this cohort as we did not detect a negative association between
261 the initial number of CD4 T cells (T_0) and r . Nevertheless, further investigation is needed to determine the
262 directionality of this relationship, and whether the extent of CD4 T cell recovery may be used as a biomarker for
263 individuals at increased risk of VL resurgence.

264 We also found that higher ratios of VL production to decline, \bar{c} , were associated with a greater risk of resurgence,
265 and larger and earlier increases in VL given that resurgence occurred. This is perhaps to be expected given that
266 \bar{c} effectively controls the amount of free virus available to infect new cells at any given time. The association
267 between \bar{c} and LPV/r adherence is also expected given that \bar{c} is a function of the protease inhibitor efficacy,
268 ϵ_2 . However, the additional associations with AZT and NVP adherence suggest \bar{c} is also capturing some of
269 the variation in reverse transcriptase inhibitor adherence through virus availability and its downstream effects
270 on cell infection rates. Finally, although we cannot isolate the contribution of drug resistance to the protease
271 inhibitor efficacy, we expect that resistance to LPV/r is rare in this cohort and is thus unlikely to be a major
272 driver of individual variation in \bar{c} , or of VL resurgence patterns.

273 Our estimate of another key parameter, the rate of latent cell reactivation ($a = 10^{-3} \text{ cells } \mu\text{l}^{-1} \text{ day}^{-1}$), is at the
274 upper limit of similar estimates from adults obtained during ART interruption ($2 \times 10^{-6} - 1 \times 10^{-3} \text{ cells}$
275 $\mu\text{l}^{-1} \text{ day}^{-1}$ [7]). Biologically, a higher burden of reactivation (a) may reflect a larger latent reservoir in these
276 infants and/or an increased per-cell rate of latent cell reactivation. Dynamically, larger reactivation estimates
277 may compensate for significant fluctuations in treatment adherence that are not included in the model. We
278 did not find any associations between a and the occurrence or size of VL resurgence. This is not surprising as
279 a effectively represents the total contribution of latent cell reactivation averaged over the entire study, and its
280 contribution to changes in VL relative to those of de novo infection events is small (Eqn. 2).

281 One unexpected result is that our simple framework can capture large variations in infant VL trajectories, including
282 monotonic decreases to sustained suppression, resurgences in VL, and suppression with subsequent re-
283 bound. Although the canonical explanation for erratic VL patterns is imperfect ART adherence, we found that
284 incorporating variation in CD4 reconstitution rates was also required to capture the complexity in our infant
285 data. In addition, we found that longer durations of maternal prenatal ART were associated with VL resurgence,
286 which is consistent with findings from this cohort that exposure to maternal prenatal ART is associated with a
287 larger viral reservoir [29], and could not be explained by worse adherence in this group ($p > 0.2$). However, we
288 could not disentangle the effects of this variable from that of VL production to decay ratios, \bar{c} . Nevertheless, our
289 findings demonstrate that a deterministic framework with reactivation and constant ART efficacy can recapitulate
290 intricate infection dynamics, and that, with the levels of adherence achieved in this study, resurgence may
291 in fact be inevitable for infants with certain virological and CD4 T cell parameter combinations.

292 There are a number of caveats to our modeling approach. First, our model does not differentiate between short-
293 and long-lived productively infected cells, the loss of which underpins the multiphasic decline of VL in adults
294 and infants on ART [4, 30, 31], or cells that have undergone abortive infection [17]. Instead, our estimates of
295 the mean lifespan of an infected cell is effectively a weighted average of the mean lifespans of these subpopula-
296 tions. Although our averaged estimate (19 days) is longer than corresponding values in adults (0.5–6 days) [7],
297 it agrees with the median short and long-lived cell lifespans we estimated previously in a subset of these infants
298 who achieved suppression (17 days) [4]. Second, we do not explicitly model the dynamics of latently infected
299 cells as they are not directly observed. However, the parameter a in our model is effectively a ‘force of reac-
300 tivation’, which combines the effects of reservoir size and the per-cell rate of reactivation. Third, we do not
301 explicitly model non-productively infected cells. Although observed VL is likely a combination of infectious
302 and non-infectious virus, our results will hold if the ratio of these remains approximately constant over time for
303 each infant. Substantial and sustained changes in LPV/r efficacy (ϵ_2), for example, through prolonged shifts in
304 adherence levels and/or increasing drug resistance, may cause non-negligible changes in this ratio. However,
305 fluctuations in LPV/r adherence, although frequent, were usually transient (Fig S12), and we expect LPV/r re-
306 sistance in this cohort to be rare. Nevertheless, a potentially important extension of our model would be the
307 inclusion of non-productively infected cells and/or allowing changes in LPV/r efficacy over time. Lastly, we
308 fit the peripheral CD4 T cell data to the number of target cells predicted by the model ($T(t)$), rather than the
309 predicted sum of target cells, productively infected cells and latently infected cells. This approach is reasonable
310 as the frequency of infection in CD4 T cells is usually small [32], and the majority of infected cells most likely
311 reside in lymphoid tissues where infection-induced CD4 depletion is greatest [33]. We also assume all CD4 T
312 cells are equally susceptible to infection, although in reality activated cells may be more susceptible than resting
313 cells [34, 35]. However, this heterogeneity is implicitly incorporated within the transmission parameter, β , if
314 the proportion of CD4 T cells that are susceptible remains approximately constant over time.

315 Finally, we acknowledge that the ART regimens used in the LEOPARD trial may not be optimal. Although
316 considered most effective at the time of study design and implementation, more potent treatments – for example,
317 integrase inhibitors and/or broadly neutralizing antibodies – have since been approved for young infants. It will
318 be important to determine whether infants starting these newer treatments are also at risk of the inevitable
319 resurgence we have identified here.

320 In conclusion, we have extended the classic framework for HIV suppression and rebound to include more realis-

321 tic dynamics of CD4 T cell decline and reconstitution in young infants on ART. We estimated rates of reactivation
322 and reconstitution, and identified distinct phases in which dynamics were either dominated by new infection of
323 CD4 T cells, or by reactivation of the latent reservoir. Moreover, we demonstrated the importance of incorpo-
324 rating variation in CD4 reconstitution rates to capture the diversity of infant VL trajectories. Overall, our results
325 suggest that VL resurgence in perinatally-infected infants may be inevitable in certain parameter regimes, and
326 highlight the utility of mathematical modeling in understanding the dynamics of infant HIV infection.

327 Acknowledgements

328 This work is part of the EPIICAL project (<http://www.epiical.org/>), supported by the PENTA-ID foundation
329 (<http://penta-id.org/>), funded through an independent grant by ViiV Healthcare UK. Data were collected dur-
330 ing the Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial (LEOPARD) study. The
331 LEOPARD study was supported in part by the Eunice Kennedy Shriver National Institute of Child Health
332 and Human Development/National Institute of Allergy and Infectious Disease, National Institutes of Health
333 (U01HD080441), USAID/PEPFAR, the South African National HIV Programme, and South African Research
334 Chairs Initiative of the Department of Science and Technology and National Research Foundation of South
335 Africa.

336 Latency and Early neOnatal Provision of Anti-Retroviral Drugs (LEOPARD) Study Team:

337 Louise Kuhn, Elaine Abrams, Wei-Yann Tsai, Stephanie Shiau (Columbia University Medical Center, New York);
338 Caroline Tiemessen, Maria Paximadis, Sharon Shalekoff, Diana Schramm, Gayle Sherman (National Institute
339 of Communicable Diseases (NICD), Johannesburg, South Africa); Renate Strehlau, Megan Burke, Martie Con-
340 radie, Ashraf Coovadia, Ndileka Mbete, Faeziah Patel, Karl Technau (Empilweni Services and Research Unit
341 (ESRU), Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa); Grace Aldrovandi (Uni-
342 versity of California, Los Angeles); Rohan Hazra (Eunice Kennedy Shriver National Institute of Child Health
343 and Human Development); Devasena Gnanashanmugam (National Institutes of Allergy and Infectious Dis-
344 eases).

345 The EPIICAL Consortium study team:

346 Nigel Klein, Diana Gibb, Sarah Watters, Man Chan, Laura McCoy, Abdel Babiker (University College Lon-
347 don, UK); Anne-Genevieve Marcelin, Vincent Calvez (Université Pierre et Marie Curie, France); Maria Angeles
348 Munoz (Servicio Madrileño de Salud-Hospital General Universitario Gregorio Marañón, Spain); Britta Wahren
349 (Karolinska Institutet, Sweden); Caroline Foster (Imperial College Healthcare NHS Trust, London, UK); Mark
350 Cotton (Stellenbosch University-Faculty of Medicine and Health Sciences, South Africa); Merlin Robb, Jintanat
351 Ananworanich (The Henry M. Jackson Foundation for the Advancement of Military Medicine, Maryland); Polly
352 Claiden (HIV i-Base, UK); Deenan Pillay (University of KwaZulu-Natal Africa Center, South Africa); Deborah
353 Persaud (Johns Hopkins University); Rob J de Boer, Juliane Schröter, Anet J N Anelone (University of Utrecht,
354 Netherlands); Thanyawee Puthanakit (Thai Red Cross AIDS-Research Centre, Thailand); Adriana Ceci, Viviana
355 Giannuzzi (Consorzio per Valutazioni Biologiche e Farmacologiche, Italy); Kathrine Luzuriaga (University of
356 Massachusetts Medical School, Worcester, Massachusetts); Nicolas Chomont (Centre de Recherche du Centre
357 Hospitalier de l'Université de Montreal-University of Montreal, Canada); Mark Cameron (Case Western Reserve
358 University, Cleveland, Ohio); Caterina Cancrini (Università degli Studi di Roma Tor Vergata, Italy); Andrew J
359 Yates, Louise Kuhn, Sinead E Morris (Columbia University Medical Center, New York); Avy Violari, Kennedy
360 Otwombe (University of the Witwatersrand, Johannesburg [PHRU], South Africa); Ilaria Pepponi, Francesca
361 Rocchi (Children's Hospital "Bambino Gesù", Rome, Italy); Stefano Rinaldi (University of Miami, Miller School
362 of Medicine, Florida); Alfredo Tagarro (Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain);
363 Maria Grazia Lain, Paula Vaz (Fundação Ariel Glaser contra o SIDA Pediátrico, Mozambique); Elisa Lopez,
364 Tacita Nhampossa (Fundação Manhiça, Mozambique).

365 We thank Juliane Schröter and Rob de Boer for critical reading and helpful suggestions.

References

- 366 1. UNAIDS data; 2020. Available from: [https://www.unaids.org/en/resources/documents/2020/](https://www.unaids.org/en/resources/documents/2020/unaids-data)
367 [unaids-data](https://www.unaids.org/en/resources/documents/2020/unaids-data).
368
- 369 2. Luzuriaga K, Gay H, Ziemniak C, et al. Viremic Relapse after HIV-1 Remission in a Perinatally Infected
370 Child. *New England Journal of Medicine*. 2015;372(8):786–788. doi:10.1056/NEJMc1413931.
- 371 3. Violari A, Cotton M, Kuhn L, et al. A child with perinatal HIV infection and long-term sustained virological
372 control following antiretroviral treatment cessation. *Nat Comm*. 2019;10(412):1–11. doi:10.1038/s41467-
373 019-08311-0.
- 374 4. Morris SE, Dziobek-Garrett L, Strehlau R, et al. Quantifying the dynamics of HIV de-
375 cline in perinatally-infected neonates on antiretroviral therapy. *JAIDS*. 2020;85(2):209–218.
376 doi:10.1097/QAI.0000000000002425.
- 377 5. Kim H, Perelson AS. Viral and Latent Reservoir Persistence in HIV-1-Infected Patients on Therapy. *PLOS*
378 *Computational Biology*. 2006;2(10):1–16. doi:10.1371/journal.pcbi.0020135.
- 379 6. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell
380 HIV-1 infection without accelerating the decay of latent infection. *Proceedings of the National Academy of*
381 *Sciences*. 2012;109(24):9523–9528. doi:10.1073/pnas.1120248109.
- 382 7. Luo R, Piovoso MJ, Martinez-Picado J, et al. HIV Model Parameter Estimates from Interrup-
383 tion Trial Data including Drug Efficacy and Reservoir Dynamics. *PLoS One*. 2012;7(7):1–12.
384 doi:10.1371/journal.pone.0040198.
- 385 8. Hill AL, Rosenbloom DIS, Fu F, et al. Predicting the outcomes of treatment to eradicate the la-
386 tent reservoir for HIV-1. *Proceedings of the National Academy of Sciences*. 2014;111(37):13475–13480.
387 doi:10.1073/pnas.1406663111.
- 388 9. Petravic J, Rasmussen TA, Lewin SR, et al. Relationship between Measures of HIV Reactivation and
389 Decline of the Latent Reservoir under Latency-Reversing Agents. *Journal of Virology*. 2017;91(9).
390 doi:10.1128/JVI.02092-16.
- 391 10. Reeves DB, Duke ER, Hughes SM, et al. Anti-proliferative therapy for HIV cure: a compound interest
392 approach. *Scientific Reports*. 2017;7(4011). doi:10.1038/s41598-017-04160-3.
- 393 11. Hill AL, Rosenbloom DIS, Nowak MA, et al. Insight into treatment of HIV infection from viral dynamics
394 models. *Immunological Reviews*. 2018;285(1):9–25. doi:<https://doi.org/10.1111/imr.12698>.
- 395 12. Prague M, Gerold JM, Balelli I, et al. Viral rebound kinetics following single and combination immunother-
396 apy for HIV/SIV. *bioRxiv*. 2019;doi:10.1101/700401.
- 397 13. Huenecke S, Behl M, Fadler C, et al. Age-matched lymphocyte subpopulation reference values in child-
398 hood and adolescence: application of exponential regression analysis. *European journal of haematology*.
399 2008;80(6):532–539.

- 400 14. Schröter J, Anelone AJN, de Boer RJ. Quantification of CD4 recovery in early-treated infants living with
401 HIV. *In revision*. 2021;.
- 402 15. Kuhn L, Strehlau R, Shiao S, et al. Early antiretroviral treatment of infants to attain HIV remission. *Eclinical
403 Medicine*. 2020;18. doi:10.1016/j.eclinm.2019.100241.
- 404 16. Morris SE, Dziobek-Garrett L, Yates AJ. ushr: Understanding suppression of HIV in R. *BMC Bioinformatics*.
405 2020;21(52). doi:10.1186/s12859-020-3389-x.
- 406 17. Ke R, er Cong M, Li D, et al. On the Death Rate of Abortively Infected Cells: Estimation from Simian-Human
407 Immunodeficiency Virus Infection. *Journal of Virology*. 2017;91(18):e00352–17. doi:10.1128/JVI.00352-17.
- 408 18. Ramratnam B, Bonhoeffer S, Binley J, et al. Rapid production and clearance of HIV-1 and hepatitis C
409 virus assessed by large volume plasma apheresis. *Lancet*. 1999;354(9192):1782–1785. doi:10.1016/S0140-
410 6736(99)02035-8.
- 411 19. Payne H, Lawrie D, Nieuwoudt M, et al. Comparison of Lymphocyte Subset Populations in Children From
412 South Africa, US and Europe. *Frontiers in Pediatrics*. 2020;8:406. doi:10.3389/fped.2020.00406.
- 413 20. Mould D, Upton R. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Devel-
414 opment – Part 2: Introduction to Pharmacokinetic Modeling Methods. *CPT: Pharmacometrics & Systems
415 Pharmacology*. 2013;2(4):38. doi:10.1038/psp.2013.14.
- 416 21. Monolix version 2020R1. Antony, France: Lixosoft SAS; 2020. Available from: [http://lixoft.com/
417 products/monolix/](http://lixoft.com/products/monolix/).
- 418 22. Castro M, de Boer RJ. Testing structural identifiability by a simple scaling method. *PLOS Computational
419 Biology*. 2020;16(11):1–15. doi:10.1371/journal.pcbi.1008248.
- 420 23. R Development Core Team. R: A Language and Environment for Statistical Computing; 2008. Available
421 from: <http://www.r-project.org>.
- 422 24. Soetaert K, Petzoldt T, Setzer RW. Solving Differential Equations in R: Package deSolve. *Journal of Statistical
423 Software*. 2010;33(9):1–25. doi:10.18637/jss.v033.i09.
- 424 25. Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. *Journal of Open Source Software*.
425 2019;4(43):1686. doi:10.21105/joss.01686.
- 426 26. Wilke CO. cowplot: Streamlined Plot Theme and Plot Annotations for 'ggplot2'; 2020. Available from:
427 <https://CRAN.R-project.org/package=cowplot>.
- 428 27. Pedersen TL. patchwork: The Composer of Plots; 2020. Available from: [https://CRAN.R-project.org/
429 package=patchwork](https://CRAN.R-project.org/package=patchwork).
- 430 28. Callaway D, Perelson A. HIV-1 infection and low steady state viral loads. *Bull Math Biol*. 2002;64(1):29–64.
431 doi:10.1006/bulm.2001.0266.
- 432 29. Kuhn L, Paximadis M, Da Costa Dias B, et al. Predictors of cell-associated HIV-1 DNA over one year in
433 very early treated infants. *Clinical Infectious Diseases*. 2021;ciab586. doi:10.1093/cid/ciab586.

- 434 30. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: viron clear-
435 ance rate, infected cell life-span, and viral generation time. *Science*. 1996;271(5255):1582–1586.
436 doi:10.1126/science.271.5255.1582.
- 437 31. Luzuriaga K, Wu H, McManus M, et al. Dynamics of human immunodeficiency virus type 1 replication in
438 vertically infected infants. *J Virol*. 1999;73(1):362–367.
- 439 32. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in
440 HIV-1 infection. *Nature*. 1997;387(6629):183–188.
- 441 33. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 Infection Is Associated with Preferential
442 Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract. *Journal of Experimental*
443 *Medicine*. 2004;200(6):761–770.
- 444 34. Pan X, Baldauf HM, Keppler OT, et al. Restrictions to HIV-1 replication in resting CD4+ T lymphocytes.
445 *Cell Res*. 2013;23(7):876–85. doi:10.1038/cr.2013.74.
- 446 35. Zack JA, Kim SG, Vatakis DN. HIV restriction in quiescent CD4+ T cells. *Retrovirology*. 2013;10:37.
447 doi:10.1186/1742-4690-10-37.

Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy

Sinead E. Morris¹, Renate Strehlau², Stephanie Shiau^{3,4}, Elaine J. Abrams^{4,5,6},
Caroline T. Tiemessen⁷, Louise Kuhn^{3,4}, Andrew J. Yates¹,
on behalf of the EPIICAL Consortium and the LEOPARD study team

¹Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA

²Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

³Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA

⁴Department of Epidemiology, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA

⁵ICAP at Columbia University, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA

⁶Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University Medical Center, New York, NY, USA

⁷Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services, and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Supplementary Information

Additional information on infant adherence

At each study visit, the infant's caregiver provided additional information for a questionnaire taken by the attending physician. Caregivers were asked if any doses had been missed since the previous visit and, if so, how many. They were also asked about any challenges administering the medication, including drug tolerance issues (e.g. if the infant spit up the medicine and repeat doses were required).

This information was a valuable supplement to estimates of adherence calculated from the amount of medication returned at the visit, given that these were often missing (due to leftover medication spilling or being left at home). If a particular adherence estimate was missing, we checked the corresponding questionnaire; if the physician noted serious adherence concerns for that drug, such as a series of missed doses, adherence was labeled as 'poor'. See Fig S10 for the resulting time series.

Model

Starting with the original set of equations

$$\begin{aligned}\frac{dT}{dt} &= \theta(t, T) - (1 - \epsilon_1)\beta VT \\ \frac{dI}{dt} &= \rho(1 - \epsilon_1)\beta VT - dI + a \\ \frac{dV}{dt} &= (1 - \epsilon_2)pI - cV,\end{aligned}$$

we assume that viral dynamics occur on a faster timescale than those of CD4 T cells, i.e. $dV/dt = 0$. This gives $I = cV/(1 - \epsilon_2)p$, and we can rewrite the above equations as

$$\begin{aligned}\frac{dT}{dt} &= \theta(t, T) - (1 - \epsilon_1)\beta VT \\ \frac{c}{(1 - \epsilon_2)p} \frac{dV}{dt} &= \rho(1 - \epsilon_1)\beta VT - d \frac{cV}{(1 - \epsilon_2)p} + a,\end{aligned}$$

i.e.

$$\begin{aligned}\frac{dT}{dt} &= \theta(t, T) - (1 - \epsilon_1)\beta VT \\ \frac{dV}{dt} &= \rho \frac{(1 - \epsilon_2)p}{c} (1 - \epsilon_1)\beta VT - dV + a \frac{(1 - \epsilon_2)p}{c}.\end{aligned}$$

Setting $\beta_0 = (1 - \epsilon_1)\beta$ and $\bar{c} = (1 - \epsilon_2)p/c$ then gives the reduced system,

$$\begin{aligned}\frac{dT}{dt} &= \theta(t, T) - \beta_0 VT \\ \frac{dV}{dt} &= \rho \bar{c} \beta_0 VT - dV + a \bar{c}.\end{aligned}$$

Structural Identifiability

We explore the structural identifiability of the equations using the approach of Castro and de Boer (2020) [1]. First, we define scaling factors for all parameters we want to estimate, i.e. u_{β_0} , $u_{\bar{c}}$, u_d , u_a and $u_{\bar{r}}$. The scaling factors for all fixed parameters are equal to one. Similarly, since both V and T are observed, we do not need to define any variable scaling factors.

Next, we equate all functionally independent terms in our equations that contain these parameters to their scaled counterparts:

$$\begin{aligned}u_{\bar{r}} \bar{r} = \bar{r} &\quad \Leftrightarrow \quad u_{\bar{r}} = 1 \\ -u_{\beta_0} \beta_0 VT = -\beta_0 VT &\quad \Leftrightarrow \quad u_{\beta_0} = 1 \\ \rho u_{\bar{c}} \bar{c} u_{\beta_0} \beta_0 VT = \rho \bar{c} \beta_0 VT &\quad \Leftrightarrow \quad u_{\bar{c}} = 1 \quad \text{since } u_{\beta_0} = 1 \\ -u_d dV = -dV &\quad \Leftrightarrow \quad u_d = 1 \\ u_a a u_{\bar{c}} \bar{c} = a \bar{c} &\quad \Leftrightarrow \quad u_a = 1 \quad \text{since } u_{\bar{c}} = 1.\end{aligned}$$

Since all scaling factors have solution equal to 1, all estimated parameters are identifiable. Note that we assume r is identifiable if \bar{r} is identifiable and T_R is fixed.

Nonlinear Mixed Effects Modeling in Monolix

We fit the following system of equations in Monolix,

$$\begin{aligned}\frac{dT}{dt} &= -b_1 b_0 e^{b_1 t} + \bar{r} - \beta_0 VT \\ \frac{dV}{dt} &= \rho \bar{c} \beta_0 VT - dV + a \bar{c}.\end{aligned}$$

All VL observations below the detection threshold of 20 copies ml^{-1} are treated as censored values. In line with previous pharmacokinetic and viral dynamics modeling, we assumed both $V(t)$ and $T(t)$ were lognormally distributed with combined error models, i.e. for variable $X_i(t)$, the residual error is expressed as the sum of a constant term and a term proportional to $X_i(t)$ ('combined1' in Monolix) [2–4].

We fix b_0 , b_1 and ρ across infants to the values given in Table 1. Initially we fix $T_R = 190$ days across all infants, but subsequently explore fits when this value is varied, and when it is freely estimated. All other parameters were estimated and assumed to have both fixed and random effects. Guided by exploratory fits, each estimated parameter was assumed to follow a lognormal distribution, with the exception of a which followed a logit-normal distribution between 0 and 0.1, and r which followed a normal distribution, and T_R which also followed a normal distribution (when estimated). Initial estimates for all population parameters are given in Table S3. Initial estimates for the residual error models were kept at their default values. Following exploratory fits, we allowed for a correlation between β_0 and d , but assumed all other parameters were independent.

Supplementary Figures and Tables

Table S1: Summary of the clinical covariates included in our analyses.

Covariate	Group	N	Variable treatment
Sex	Male	59	Categorical
	Female	63	
Preterm	Yes	88	Categorical
	No	103	
Delivery mode	Normal vaginal delivery	87	Categorical
	Caesarean section	35	
Birth weight (g)	<2500	29	Continuous
	2500+	93	
Age at ART initiation (days)	<2	49	Categorical
	2–14	56	
	14+	17	
Pre-treatment CD4 percentage	<35	33	Continuous
	35+	61	
	Not recorded	28	
Mother's viral load (copies ml ⁻¹)	<1000	32	Continuous
	1000+	90	
Mother's CD4 count (cells μl^{-1})	<350	61	Continuous
	350+	61	
Mother's CD4 percent	<25	77	Continuous
	25+	45	
Maternal prenatal ART history	None	25	Categorical
	Initiated 12+ weeks into pregnancy	37	
	Initiated <12 weeks into pregnancy	41	
	Initiated before pregnancy	18	
	Unknown	1	
Breastfeeding	Some	96	Categorical
	None	26	

Table S2: Comparing models with T_R fixed across all infants. The AIC difference for model i was calculated as $AIC_i - AIC_{min}$, where AIC_{min} is the minimum AIC value across all models. The model with zero difference is the model with lowest AIC and thus is the most strongly favored.

Fixed value of T_R (days)	AIC difference
170	38.6
190	34.8
210	25.9
215	23.6
220	10.5
223	8.3
225	0.0
227	24.4
230	13.2
240	30.3
250	22.8
270	30.8
300	43.2

Table S3: Initial estimates for the population parameters in Monolix.

Parameter	Distribution	Fixed effect	Standard Deviation of Random Effects
β_0	Lognormal	1×10^{-6}	0.1
\bar{c}	Lognormal	100	1
d	Lognormal	0.3	0.1
a	Logitnormal (0-0.1)	0.01	0.1
r	Normal	9	0.25
T_R^*	Normal	225	2
T_A^*	Normal	365	2
T_0	Lognormal	3500	1
V_0	Lognormal	10,000	1

*when estimated




Figure S1: **The standard model for adult CD4 T cell dynamics does not capture infant data.** Each panel represents a different infant, points represent the data, and solid lines are the model fits. Here $\theta(t, T) = \lambda - d_T T$, with λ and d_T assumed to have lognormal distributions. Initial estimates for the population mean were 1000 cells $\mu\text{l}^{-1} \text{ day}^{-1}$ and 0.25 day^{-1} , respectively, and for the standard deviation were 1 and 0.1, respectively. The nonlinear mixed effects fitting procedure was as described in the main text.




Figure S2: **Sensitivity of VL predictions to model parameters.** Each fixed (A) or estimated (B) parameter was varied within 20% of its original value while keeping all other parameters at their original values. Original values for the estimated parameters were the population-level means from the best-fit model. Note that predictions for ρ do not include 10% and 20% increases as these are biologically unrealistic (i.e. a fraction > 1).




Figure S3: **Sensitivity of CD4 T cell predictions to model parameters.** Each fixed (A) or estimated (B) parameter was varied within 20% of its original value while keeping all other parameters at their original values. Original values for the estimated parameters were the population-level means from the best-fit model. Note that predictions for ρ do not include 10% and 20% increases as these are biologically unrealistic (i.e. a fraction > 1).




Figure S4: **Relative contribution of factors driving an increase in productively infected cells.** Each panel represents an infant, and red shaded regions show their VL scaled by its maximum value.




Figure S5: **VL and CD4 T cell dynamics influence the time at which reactivation contributes most to productively infected cell growth.** Each point represents a different infant with respect to the time at which reactivation became the major contributor to productively infected cell growth and the time at which: (A) their VL started increasing (if applicable); (B) their VL finished increasing (if applicable); and (C) their CD4 T cell recovery plateaued (T_R). Correlations are 0.45, 0.71 and 0.29, respectively, and $p < 0.05$ in all cases. Note that the correlation in (C) is reduced to a trend ($p = 0.05$) when the infant with the lowest T_R is removed.






Figure S7: **Correlations between estimated parameters.** The colour scale shows the strength of the correlation; those with p -values greater than a significance threshold of 0.05 are crossed out. p -values were adjusted using the Benjamini-Hochberg correction. The strong correlation between β_0 and d was included in the nonlinear mixed effects model framework.




Figure S8: **Longer duration of maternal ART is associated with greater VL production to decay ratios.** The ratio is given by $\bar{c} = (1 - \epsilon_2)p/c$, in copies $\text{ml}^{-1} \text{cell}^{-1}$. Each point represents a different infant. Significance levels are $p < 0.01$ (**); $p < 0.001$ (***).




Figure S9: **LPV/r adherence estimated from returned medication.** Each line represents a different infant.



Figure S10: **Reported adherence trajectories.** Adherence estimates greater than 90% were labeled 'good'; and all others 'poor'. Each panel is a different infant.

References

1. Castro M, de Boer RJ. Testing structural identifiability by a simple scaling method. *PLOS Computational Biology*. 2020;16(11):1–15. doi:10.1371/journal.pcbi.1008248.
2. Prague M, Gerold JM, Balelli I, et al. Viral rebound kinetics following single and combination immunotherapy for HIV/SIV. *bioRxiv*. 2019;doi:10.1101/700401.
3. Monolix version 2020R1. Antony, France: Lixosoft SAS; 2020. Available from: <http://lixoft.com/products/monolix/>.
4. Mould D, Upton R. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development – Part 2: Introduction to Pharmacokinetic Modeling Methods. *CPT: Pharmacometrics & Systems Pharmacology*. 2013;2(4):38. doi:10.1038/psp.2013.14.